Abcellera Common Stock vs Short Long Term Debt Analysis
ABCL Stock | USD 3.64 0.14 3.70% |
Abcellera BiologicsInc financial indicator trend analysis is way more than just evaluating Abcellera BiologicsInc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Abcellera BiologicsInc is a good investment. Please check the relationship between Abcellera BiologicsInc Common Stock and its Short Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera BiologicsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.
Common Stock vs Short Long Term Debt
Common Stock vs Short Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Abcellera BiologicsInc Common Stock account and Short Long Term Debt. At this time, the significance of the direction appears to have pay attention.
The correlation between Abcellera BiologicsInc's Common Stock and Short Long Term Debt is -0.99. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Short Long Term Debt in the same time period over historical financial statements of Abcellera BiologicsInc, assuming nothing else is changed. The correlation between historical values of Abcellera BiologicsInc's Common Stock and Short Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Abcellera BiologicsInc are associated (or correlated) with its Short Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt has no effect on the direction of Common Stock i.e., Abcellera BiologicsInc's Common Stock and Short Long Term Debt go up and down completely randomly.
Correlation Coefficient | -0.99 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Common Stock
Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Most indicators from Abcellera BiologicsInc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Abcellera BiologicsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera BiologicsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.At this time, Abcellera BiologicsInc's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 1.68 this year, although the value of Tax Provision is projected to rise to (26.2 M).
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.8M | 59.7M | 30.9M | 20.4M | Interest Income | 3.3M | 16.1M | 42.2M | 44.4M |
Abcellera BiologicsInc fundamental ratios Correlations
Click cells to compare fundamentals
Abcellera BiologicsInc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Abcellera BiologicsInc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 23.5M | 1.0B | 1.3B | 1.5B | 1.5B | 989.6M | |
Short Long Term Debt Total | 6.9M | 6.1M | 36.4M | 82.3M | 77.4M | 39.0M | |
Other Current Liab | 129.3K | 76.7M | 77.5M | 58.0M | 61.3M | 50.2M | |
Total Current Liabilities | 7.9M | 103.5M | 120.7M | 118.3M | 119.0M | 87.2M | |
Total Stockholder Equity | 10.3M | 830.5M | 1.0B | 1.2B | 1.2B | 781.7M | |
Other Liab | 1.3M | 65.6M | 134.0M | 112.6M | 129.5M | 69.6M | |
Net Tangible Assets | 2.7M | 683.9M | 829.5M | 1.1B | 1.2B | 1.3B | |
Property Plant And Equipment Net | 8.5M | 17.9M | 111.6M | 217.3M | 287.7M | 302.1M | |
Current Deferred Revenue | 3.2M | 6.6M | 7.5M | 21.6M | 26.1M | 27.4M | |
Net Debt | (661.9K) | (588.0M) | (439.7M) | (304.3M) | (55.9M) | (58.7M) | |
Retained Earnings | (4.7M) | 114.2M | 267.7M | 426.2M | 279.8M | 198.1M | |
Accounts Payable | 1.6M | 20.0M | 32.0M | 33.2M | 25.5M | 20.9M | |
Cash | 7.6M | 594.1M | 476.1M | 386.5M | 133.3M | 126.7M | |
Non Current Assets Total | 10.8M | 192.2M | 388.8M | 515.4M | 616.1M | 317.1M | |
Cash And Short Term Investments | 7.6M | 594.1M | 723.0M | 886.5M | 760.6M | 546.7M | |
Net Receivables | 4.4M | 213.2M | 160.6M | 38.6M | 64.4M | 89.0M | |
Common Stock Total Equity | 5.1M | 710.4M | 722.4M | 734.4M | 844.5M | 479.0M | |
Common Stock Shares Outstanding | 154.1M | 269.5M | 318.3M | 314.8M | 289.2M | 290.3M | |
Liabilities And Stockholders Equity | 23.5M | 1.0B | 1.3B | 1.5B | 1.5B | 989.6M | |
Non Current Liabilities Total | 5.3M | 71.5M | 172.2M | 189.3M | 216.8M | 120.7M | |
Capital Lease Obligations | 3.1M | 3.7M | 36.4M | 82.3M | 77.4M | 81.2M | |
Other Current Assets | 1.8M | 6.0M | 21.2M | 75.4M | 20.9M | 23.1M | |
Other Stockholder Equity | 2.3M | 5.9M | 35.4M | 74.1M | 121.1M | 127.1M | |
Total Liab | 13.2M | 175.0M | 292.8M | 307.6M | 335.8M | 208.0M | |
Net Invested Capital | 6.5M | 832.9M | 1.0B | 1.2B | 1.2B | 780.7M | |
Property Plant And Equipment Gross | 8.5M | 17.9M | 121.4M | 235.7M | 318.3M | 334.2M | |
Total Current Assets | 12.6M | 813.3M | 929.8M | 1.0B | 872.0M | 672.5M | |
Capital Stock | 12.7M | 710.4M | 722.4M | 734.4M | 753.2M | 540.0M | |
Net Working Capital | 4.7M | 709.8M | 809.1M | 907.2M | 753.0M | 585.3M | |
Short Term Debt | 2.9M | 190K | 3.7M | 5.6M | 6.2M | 3.9M | |
Common Stock | 5.1M | 710.4M | 722.4M | 734.4M | 753.2M | 537.3M | |
Property Plant Equipment | 8.5M | 17.9M | 111.6M | 217.3M | 249.8M | 262.3M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Abcellera BiologicsInc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera BiologicsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.Note that the Abcellera BiologicsInc information on this page should be used as a complementary analysis to other Abcellera BiologicsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Abcellera Stock analysis
When running Abcellera BiologicsInc's price analysis, check to measure Abcellera BiologicsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abcellera BiologicsInc is operating at the current time. Most of Abcellera BiologicsInc's value examination focuses on studying past and present price action to predict the probability of Abcellera BiologicsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abcellera BiologicsInc's price. Additionally, you may evaluate how the addition of Abcellera BiologicsInc to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Abcellera BiologicsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera BiologicsInc. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera BiologicsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.51) | Revenue Per Share 0.131 | Quarterly Revenue Growth (0.57) | Return On Assets (0.1) |
The market value of Abcellera BiologicsInc is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera BiologicsInc's value that differs from its market value or its book value, called intrinsic value, which is Abcellera BiologicsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera BiologicsInc's market value can be influenced by many factors that don't directly affect Abcellera BiologicsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera BiologicsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera BiologicsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera BiologicsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.